J. Biol. Chem., Vol. 266, Issue 13, 8129-8135, 05, 1991

Role of lysine 173 in heparin binding to heparin cofactor II

HC Whinna, MA Blinder, M Szewczyk, DM Tollefsen and FC Church
Department of Pathology, University of North Carolina, Chapel Hill 27599.

Heparin cofactor II (HC) is a plasma serine proteinase inhibitor (serpin) that inhibits alpha-thrombin in a reaction that is dramatically enhanced by heparin and other glycosaminoglycans/polyanions. We investigated the glycosaminoglycan binding site in HC by: (i) chemical modification with pyridoxal 5'- phosphate (PLP) in the absence and presence of heparin and dermatan sulfate; (ii) molecular modeling; and (iii) site-directed oligonucleotide mutagenesis. Four lysyl residues (173, 252, 343, and 348) were protected from modification by heparin and to a lesser extent by dermatan sulfate. Heparin-protected PLPHC retained both heparin cofactor and dermatan sulfate cofactor activity while dermatan sulfate- protected PLPHC retained some dermatan sulfate cofactor activity and little heparin cofactor activity. Molecular modeling studies revealed that Lys173 and Lys252 are within a region previously shown to contain residues involved in glycosaminoglycan binding. Lys343 and Lys348 are distant from this region, but protection by heparin and dermatan sulfate might result from a conformational change following glycosaminoglycan binding to the inhibitor. Site-directed mutagenesis of Lys173 and Lys343 was performed to further dissect the role of these two regions during HC-heparin and HC-dermatan sulfate interactions. The Lys343----Asn or Thr mutants had normal or only slightly reduced heparin or dermatan sulfate cofactor activity and eluted from heparin- Sepharose at the same ionic strength as native recombinant HC. However, the Lys173----Gln or Leu mutants had greatly reduced heparin cofactor activity and eluted from heparin-Sepharose at a significantly lower ionic strength than native recombinant HC but retained normal dermatan sulfate cofactor activity. Our results demonstrate that Lys173 is involved in the interaction of HC with heparin but not with dermatan sulfate, whereas Lys343 is not critical for HC binding to either glycosaminoglycan. These data provide further evidence for the determinants required for glycosaminoglycan binding to HC.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. He, T. K. Giri, C. P. Vicente, and D. M. Tollefsen Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II Blood, April 15, 2008; 111(8): 4118 - 4125. [Abstract] [Full Text] [PDF]

				D. M. Tollefsen Heparin Cofactor II Modulates the Response to Vascular Injury Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 454 - 460. [Abstract] [Full Text] [PDF]

				Y. M. Fortenberry, H. C. Whinna, H. R. Gentry, T. Myles, L. L. K. Leung, and F. C. Church Molecular Mapping of the Thrombin-Heparin Cofactor II Complex J. Biol. Chem., October 8, 2004; 279(41): 43237 - 43244. [Abstract] [Full Text] [PDF]

				H. He, Y. Dang, F. Dai, Z. Guo, J. Wu, X. She, Y. Pei, Y. Chen, W. Ling, C. Wu, et al. Post-translational Modifications of Three Members of the Human MAP1LC3 Family and Detection of a Novel Type of Modification for MAP1LC3B J. Biol. Chem., August 1, 2003; 278(31): 29278 - 29287. [Abstract] [Full Text] [PDF]

				Y. Hayakawa, T. Hayashi, J.-B. Lee, T. Ozawa, and N. Sakuragawa Activation of Heparin Cofactor II by Calcium Spirulan J. Biol. Chem., April 6, 2000; 275(15): 11379 - 11382. [Abstract] [Full Text] [PDF]

				P. C. Y. Liaw, R. C. Austin, J. C. Fredenburgh, A. R. Stafford, and J. I. Weitz Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II J. Biol. Chem., September 24, 1999; 274(39): 27597 - 27604. [Abstract] [Full Text] [PDF]

				M. S. G. Pavao, K. R. M. Aiello, C. C. Werneck, L. C. F. Silva, A.-P. Valente, B. Mulloy, N. S. Colwell, D. M. Tollefsen, and P. A. S. Mourao Highly Sulfated Dermatan Sulfates from Ascidians. STRUCTURE VERSUS ANTICOAGULANT ACTIVITY OF THESE GLYCOSAMINOGLYCANS J. Biol. Chem., October 23, 1998; 273(43): 27848 - 27857. [Abstract] [Full Text] [PDF]

				A. V. Ciaccia, D. M. Monroe, and F. C. Church Arginine 200 of Heparin Cofactor II Promotes Intramolecular Interactions of the Acidic Domain. IMPLICATION FOR THROMBIN INHIBITION J. Biol. Chem., May 30, 1997; 272(22): 14074 - 14079. [Abstract] [Full Text] [PDF]

				S. T. Cooper, L. L. Neese, M. N. DiCuccio, D. K. Liles, M. Hoffman, and F. C. Church Vascular Localization of the Heparin-binding Serpins Antithrombin, Heparin Cofactor II, and Protein C Inhibitor Clinical and Applied Thrombosis/Hemostasis, July 1, 1996; 2(3): 185 - 191. [Abstract] [PDF]

				V. C. Chen, L. Chao, and J. Chao A Positively Charged Loop on the Surface of Kallistatin Functions to Enhance Tissue Kallikrein Inhibition by Acting as a Secondary Binding Site for Kallikrein J. Biol. Chem., December 15, 2000; 275(51): 40371 - 40377. [Abstract] [Full Text] [PDF]

				V. C. Chen, L. Chao, D. C. Pimenta, G. Bledsoe, L. Juliano, and J. Chao Identification of a Major Heparin-binding Site in Kallistatin J. Biol. Chem., January 5, 2001; 276(2): 1276 - 1284. [Abstract] [Full Text] [PDF]